Medgenics' $9.5M private placement to fuel Biopump clinical trials

Israel's Medgenics ($MDGN) will use a newly-raised $9.5 million private placement to advance clinical trials for its Biopump technology.

The technology is designed to regularly produce and deliver therapeutic proteins to patients using their own skin biopsy. Medgenics president and CEO Andrew Pearlman said in a statement that the money will help advance clinical trials for its Epodure Biopump treatment, which produces erythropoietin to treat anemia, and Infradure Biopump, which makes interferon-alpha to treat hepatitis.

Pearlman added that the money will also be used to bring the company's technology toward commercialization. Medgenics, which is also based in San Francisco, confirmed in November that it was moving ahead with plans to continue clinical testing of its technology to treat chronic kidney disease.

- read the release

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.